Morgan Stanley
SANA icon

Morgan Stanley’s Sana Biotechnology SANA Stock Holding History

Morgan Stanley’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.2M Buy
1,460,015
+174,970
+14% +$689K ﹤0.01% 4262
2025
Q4 		$5.23M Buy
1,285,045
+408,540
+47% +$1.83M ﹤0.01% 4136
2025
Q3 		$3.11M Sell
876,505
-603,290
-41% -$2.18M ﹤0.01% 4503
2025
Q2 		$4.04M Buy
1,479,795
+654,131
+79% +$1.35M ﹤0.01% 4230
2025
Q1 		$1.39M Sell
825,664
-1,084,555
-57% -$3.03M ﹤0.01% 4830
2024
Q4 		$3.11M Buy
1,910,219
+7,154
+0.4% +$21.3K ﹤0.01% 4370
2024
Q3 		$7.92M Buy
1,903,065
+284,724
+18% +$1.5M ﹤0.01% 3614
2024
Q2 		$8.84M Buy
1,618,341
+128,661
+9% +$1.03M ﹤0.01% 3412
2024
Q1 		$14.9M Buy
1,489,680
+22,876
+2% +$171K ﹤0.01% 2995
2023
Q4 		$5.98M Buy
1,466,804
+873,841
+147% +$3.22M ﹤0.01% 4268
2023
Q3 		$2.29M Buy
592,963
+3,140
+0.5% +$16.9K ﹤0.01% 4300
2023
Q2 		$3.52M Buy
589,823
+104,082
+21% +$600K ﹤0.01% 4026
2023
Q1 		$1.59M Buy
485,741
+37,587
+8% +$150K ﹤0.01% 4589
2022
Q4 		$1.77M Sell
448,154
-247,231
-36% -$1.21M ﹤0.01% 4536
2022
Q3 		$4.17M Sell
695,385
-231,638
-25% -$1.67M ﹤0.01% 3842
2022
Q2 		$5.96M Sell
927,023
-858,870
-48% -$5.47M ﹤0.01% 3601
2022
Q1 		$14.8M Buy
1,785,893
+1,055,116
+144% +$8.53M ﹤0.01% 2443
2021
Q4 		$11.3M Sell
730,777
-167,713
-19% -$3.23M ﹤0.01% 2821
2021
Q3 		$20.2M Buy
898,490
+39,182
+5% +$823K ﹤0.01% 2072
2021
Q2 		$16.9M Buy
859,308
+43,788
+5% +$992K ﹤0.01% 2339
2021
Q1 		$27.3M Buy
+815,520
New +$26.6M ﹤0.01% 1641

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Morgan Stanley's SANA Position: Q1 2026 in Review

Morgan Stanley increased its Sana Biotechnology (SANA) stake by 14% in Q1 2026, buying an estimated $689K and bringing the position to 1,460,015 shares worth $4.2M. The position accounts for ﹤0.01% of the portfolio, ranked #4262.

Morgan Stanley first reported a position in SANA in Q1 2021 and has held it in 21 quarters since. The position peaked at $27.3M in Q1 2021. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Morgan Stanley held 1,460,015 shares of Sana Biotechnology worth $4.2M as of Q1 2026.
  • Morgan Stanley bought 174,970 Sana Biotechnology shares in Q1 2026, an estimated $689K.
  • Sana Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4262 holding.
  • Morgan Stanley first reported a position in Sana Biotechnology in Q1 2021 and has held it in 21 quarters since.
  • Morgan Stanley's Sana Biotechnology position peaked at $27.3M in Q1 2021.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.